New data on multiple targeted agents and evolving diagnostic frameworks highlight progress in classifying and treating EGFR PACC–mutated NSCLC.
News|Videos|December 18, 2024
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
Author(s)Aditya Bardia, MD, MPH, FASCO
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups, with benefits observed particularly in earlier treatment lines and in those without prior fulvestrant exposure.
Advertisement
Advertisement
Related to this article
Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.
Five Huntsman Cancer Institute at the University of Utah colleagues earned endowed chair appointments, including new appointments.
The CHMP recommended EU approval of T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer,
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The CHMP has recommended the approval of sacituzumab govitecan/pembrolizumab for treatment-naive, PD-L1-positive metastatic TNBC in the European Union.
Overall survival was the sole US primary end point of the phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab and was not met.
Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
3
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
4
CHMP Recommends Sacituzumab Govitecan Plus Pembrolizumab for Frontline PD-L1+ Metastatic TNBC
5